Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

CAR T-cell therapy shows lasting improvements in stiff person syndrome, study finds (opens in a new tab)

medicalxpress.com · 2026-10-21

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    https://ir.kyvernatx.com/news-releases/news-release-details/kyverna-therapeutics-presents-full-one-year-registrational-data

    Where the story links (opens in a new tab)
  • The study this story reportspresented as the new finding

    https://news.cuanschutz.edu/news-stories/car-t-cell-therapy-helps-first-stiff-person-syndrome-trial-patient-walk-freely-again

    Where the story links (opens in a new tab)
The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedNew research led by the University of Colorado Anschutz is offering hope to people living with stiff person syndrome, showing that a CAR T-cell therapy may help change the course of the disease, with patients experiencing significant improvements in mobility and overall disability that lasted at least one year after treatment.View evidenceHide evidence

As statedlasting at least one year

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedThe Phase 2 clinical trial, sponsored by Kyverna Therapeutics and led by principal investigator Amanda Piquet, evaluated an experimental CAR T-cell therapy called mivocabtagene autoleucel (miv-cel).View evidenceHide evidence

As statedPhase 2

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedOne year after receiving a single treatment, patients with SPS demonstrated significant improvements in mobility, including completing a 25-foot walking test in nearly half the time it took before treatment.View evidenceHide evidence

As statednearly half the time; 49% less time

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedTwo-thirds of patients who initially needed walking aids were able to complete a walking test without assistance at one year.View evidenceHide evidence

As statedtwo-thirds (67%)

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedAt one year, 24 of 26 patients remained free of treatments that suppress or modify the immune system to manage SPS, and in 65% of patients the immune cells targeted by the treatment had begun returning while clinical improvements were maintained.View evidenceHide evidence

As stated24 of 26 (92%); 65%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe findings from this registrational clinical trial are helping advance miv-cel toward potential FDA approval, and the company says it intends to complete its rolling BLA submission in the fourth quarter of 2026.View evidenceHide evidence

As statedpotential FDA approval; fourth quarter of 2026

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Explore all search results